Clinical Trial Update: First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS) [Phase 1]

View source ↗

Summary

Genmab announced a first-in-human Phase 1 trial of GEN3018 in relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic syndrome, which is curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Higher-risk Myelodysplastic Syndrome

Drugs mentioned

• GEN3018

Snippet

Sponsor: Genmab | Conditions: R/R AML, R/R HR-MDS | Phase 1 | Status: RECRUITING